Home > Press Releases > Gene Therapy Manufacturing Market

Gene Therapy Manufacturing Market Likely to Surpass USD 5.2 Billion by 2035

Report Code: HC-36065  |  Published in: Aug 2026, By MarketGenics  |  Number of pages: 324
Get PDF
Buy

Global Gene Therapy Manufacturing Market Forecast 2035:

According to the report, the global gene therapy manufacturing market is projected to expand from USD 1.3 billion in 2025 to USD 5.2 billion by 2035, registering a CAGR of 14.8%, the highest during the forecast period. The demand for specialized manufacturing capabilities is increasing due to the expansion of gene therapy pipelines and clinical development.

Increased use of AAV and viral-vector technologies and outsourcing to specialized CDMOs are additional drivers of market growth. In January 2026, Charles River Laboratories announced an agreement with Gazi University to supply research grade AAV plasmids for rare-disease gene therapy research, as well as academic development capabilities, and support early-stage gene therapy programs, merging CDMO expertise with academic development capabilities.

Industry capacity is also growing to meet rising demand for viral vectors for clinical use, as well as for custom manufacturing services. Expanding development pipelines and outsourced manufacturing are strengthening demand for scalable, integrated gene therapy production capabilities.                        

Key Driver, Restraint, and Growth Opportunity Shaping the Global Gene Therapy Manufacturing Market

The use of more advanced process analytical technologies, real-time monitoring and data-driven controls is improving visibility of the process, batch consistency, quality assurance and operational efficiency. The capabilities allow manufacturers to detect process deviations early, fine-tune production parameters, enhance reproducibility and enable more robust and scalable manufacturing process for gene therapy.                                              

The lack of experienced professionals in GMP operations and the production of viral-vectors, analytical development, quality control and regulatory affairs can limit capacity expansion in production. Process complexity can also drive up training needs, the time to develop new workers, and potentially the operating expenses of sustaining specialized workforce through manufacturing.                       

The progress in continuous and automated plasmid DNA manufacturing offers the potential to increase production efficiency, reduce process variability and material loss, and enhance the supply of key materials for viral-vector manufacturing. Consistent quality, enhanced scalability, and reliable raw-material supply for commercial gene therapy production can also be achieved through greater process automation.             

Expansion of Global Gene Therapy Manufacturing Market

Expansion of GMP mRNA Manufacturing Infrastructure

  • Manufacturers are expanding their GMP facilities to counter the distribution of mRNA-based therapies, such as gene editing. The trend is driving the scalability of manufacturing, regulatory preparedness, and commercial supply, and allows CDMOs to cater to several advanced-therapy applications on single platforms.
  • For instance, in June 2025, Kaneka Eurogentec received Belgian health-authority accreditation for an expanded commercial mRNA GMP facility, significantly increasing production capacity and supporting mRNA manufacturing for gene-editing and other therapeutic applications.
  • Rising mRNA manufacturing capacity through expanded GMP infrastructure is helping to advance novel gene therapy modalities to the market.                                    

Regional Analysis of Global Gene Therapy Manufacturing Market

  • North America commands the highest demand in the gene therapy manufacturing market due to well-established biopharmaceutical region with a large number of developers, a well-developed GMP infrastructure, and established CDMO capabilities. In August 2026, Bristol Myers Squibb announced a $2.3 billion advanced manufacturing facility in Houston to further bolster biopharmaceutical manufacturing capacity and investment in the region. North America continues to dominate the gene therapy market in terms of manufacturing with continued expansion.
  • Asia Pacific is experiencing the fastest growth due to expanding biopharmaceutical manufacturing infrastructure, increasing clinical-trial activity, cost-competitive production capabilities, and growing adoption of advanced therapies. Additionally, localized manufacturing is gaining traction in the region, thereby enhancing regional supply capacities and bringing in global developers who are looking for scalable production and wider access to emerging markets.             

Prominent players operating in the global gene therapy manufacturing market is Andelyn Biosciences, Catalent, Inc., Charles River Laboratories, Forge Biologics, FUJIFILM Diosynth Biotechnologies, Genetix Biotherapeutics, Kaneka Eurogentec, Lonza Group AG, Merck KGaA, Novartis AG, Oxford Biomedica, Recipharm AB, Samsung Biologics, Sarepta Therapeutics, Inc., Thermo Fisher Scientific, WuXi Advanced Therapies, Others.      

The global gene therapy manufacturing market has been segmented as follows:

Global Gene Therapy Manufacturing Market Analysis, By Product Type

  • Plasmid DNA
  • Viral Vector
    • Adeno-Associated Virus (AAV)
    • Lentivirus
    • Adenovirus
    • Retrovirus (excl. Lentivirus)
    • Herpes Simplex Virus (HSV)
    • Others (Vaccinia, Poxvirus, etc.)
  • Non-Viral Vector
    • Plasmid DNA
    • Naked/Purified DNA
    • Lipid Nanoparticles (LNP)
    • Others (Polymer-based, Physical Delivery, etc.)
  • Cell-Based Components
  • Others (Media, Reagents, Consumables, etc.)

Global Gene Therapy Manufacturing Market Analysis, By Therapy Type

  • In Vivo Gene Therapy
  • Ex Vivo Gene Therapy

Global Gene Therapy Manufacturing Market Analysis, By Workflow/Process

  • Upstream Processing
    • Cell Line/Vector Expansion
    • Transfection/Infection
    • Bioreactor Production
    • Others
  • Downstream Processing
    • Purification (Chromatography, Filtration)
    • Fill-Finish
    • Formulation
    • Others 

Global Gene Therapy Manufacturing Market Analysis, By Manufacturing Mode

  • In-house/Captive Manufacturing
  • Outsourced Manufacturing

Global Gene Therapy Manufacturing Market Analysis, By Scale of Operation

  • Clinical-Scale Manufacturing
    • Pre-Clinical
    • Phase I/II/III
  • Commercial-Scale Manufacturing

Global Gene Therapy Manufacturing Market Analysis, By Therapeutic Area

  • Oncology
  • Rare & Genetic Disorders
  • Ophthalmology
  • Neurological Disorders
  • Cardiovascular Diseases
  • Hematological Disorders
  • Musculoskeletal Disorders
  • Others

Global Gene Therapy Manufacturing Market Analysis, By End User

  • Pharmaceutical Companies
  • Biotechnology Companies
  • CDMOs/CMOs
  • Academic & Research Institutes
  • Hospitals & Specialty Clinics
  • Government Research Organizations
  • Other End-users

Global Gene Therapy Manufacturing Market Analysis, By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America 

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Gene Therapy Manufacturing Market Outlook
      • 2.1.1. Gene Therapy Manufacturing Market Size (Value - US$ Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2026-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
      • 3.1.1. Healthcare & Pharmaceutical Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Expanding Gene Therapy Pipeline and Clinical Approvals
        • 4.1.1.2. Rising Demand for Scalable Viral Vector Manufacturing
        • 4.1.1.3. Increasing Adoption of Advanced and Automated Manufacturing Technologies
      • 4.1.2. Restraints
        • 4.1.2.1. High Manufacturing Costs and Capital Requirements
        • 4.1.2.2. Complex Regulatory, Quality-Control, and Batch-Consistency Requirements
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Value Chain Analysis
    • 4.5. Porter’s Five Forces Analysis
    • 4.6. PESTEL Analysis
    • 4.7. Global Gene Therapy Manufacturing Market Demand
      • 4.7.1. Historical Market Size – in Value (US$ Bn), 2020-2024
      • 4.7.2. Current and Future Market Size – in Value (US$ Bn), 2026–2035
        • 4.7.2.1. Y-o-Y Growth Trends
        • 4.7.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Gene Therapy Manufacturing Market Analysis, by Product Type
    • 6.1. Key Segment Analysis
    • 6.2. Gene Therapy Manufacturing Market Size (Value - US$ Bn), Analysis, and Forecasts, by Product Type, 2021-2035
      • 6.2.1. Plasmid DNA
      • 6.2.2. Viral Vector
        • 6.2.2.1. Adeno-Associated Virus (AAV)
        • 6.2.2.2. Lentivirus
        • 6.2.2.3. Adenovirus
        • 6.2.2.4. Retrovirus (excl. Lentivirus)
        • 6.2.2.5. Herpes Simplex Virus (HSV)
        • 6.2.2.6. Others (Vaccinia, Poxvirus, etc.)
      • 6.2.3. Non-Viral Vector
        • 6.2.3.1. Plasmid DNA
        • 6.2.3.2. Naked/Purified DNA
        • 6.2.3.3. Lipid Nanoparticles (LNP)
        • 6.2.3.4. Others (Polymer-based, Physical Delivery, etc.)
      • 6.2.4. Cell-Based Components
      • 6.2.5. Others (Media, Reagents, Consumables, etc.)
  • 7. Global Gene Therapy Manufacturing Market Analysis, by Therapy Type
    • 7.1. Key Segment Analysis
    • 7.2. Gene Therapy Manufacturing Market Size (Value - US$ Bn), Analysis, and Forecasts, by Therapy Type, 2021-2035
      • 7.2.1. In Vivo Gene Therapy
      • 7.2.2. Ex Vivo Gene Therapy
  • 8. Global Gene Therapy Manufacturing Market Analysis, by Workflow/Process
    • 8.1. Key Segment Analysis
    • 8.2. Gene Therapy Manufacturing Market Size (Value - US$ Bn), Analysis, and Forecasts, by Workflow/Process, 2021-2035
      • 8.2.1. Upstream Processing
        • 8.2.1.1. Cell Line/Vector Expansion
        • 8.2.1.2. Transfection/Infection
        • 8.2.1.3. Bioreactor Production
        • 8.2.1.4. Others
      • 8.2.2. Downstream Processing
        • 8.2.2.1. Purification (Chromatography, Filtration)
        • 8.2.2.2. Fill-Finish
        • 8.2.2.3. Formulation
        • 8.2.2.4. Others
  • 9. Global Gene Therapy Manufacturing Market Analysis, by Manufacturing Mode
    • 9.1. Key Segment Analysis
    • 9.2. Gene Therapy Manufacturing Market Size (Value - US$ Bn), Analysis, and Forecasts, by Manufacturing Mode, 2021-2035
      • 9.2.1. In-house/Captive Manufacturing
      • 9.2.2. Outsourced Manufacturing
  • 10. Global Gene Therapy Manufacturing Market Analysis, by Scale of Operation
    • 10.1. Key Segment Analysis
    • 10.2. Gene Therapy Manufacturing Market Size (Value - US$ Bn), Analysis, and Forecasts, by Scale of Operation, 2021-2035
      • 10.2.1. Clinical-Scale Manufacturing
        • 10.2.1.1. Pre-Clinical
        • 10.2.1.2. Phase I/II/III
      • 10.2.2. Commercial-Scale Manufacturing
  • 11. Global Gene Therapy Manufacturing Market Analysis, by Therapeutic Area
    • 11.1. Key Segment Analysis
    • 11.2. Gene Therapy Manufacturing Market Size (Value - US$ Bn), Analysis, and Forecasts, by Therapeutic Area, 2021-2035
      • 11.2.1. Oncology
      • 11.2.2. Rare & Genetic Disorders
      • 11.2.3. Ophthalmology
      • 11.2.4. Neurological Disorders
      • 11.2.5. Cardiovascular Diseases
      • 11.2.6. Hematological Disorders
      • 11.2.7. Musculoskeletal Disorders
      • 11.2.8. Others
  • 12. Global Gene Therapy Manufacturing Market Analysis, by End User
    • 12.1. Key Segment Analysis
    • 12.2. Gene Therapy Manufacturing Market Size (Value - US$ Bn), Analysis, and Forecasts, by End User, 2021-2035
      • 12.2.1. Pharmaceutical Companies
      • 12.2.2. Biotechnology Companies
      • 12.2.3. CDMOs/CMOs
      • 12.2.4. Academic & Research Institutes
      • 12.2.5. Hospitals & Specialty Clinics
      • 12.2.6. Government Research Organizations
      • 12.2.7. Other End-users
  • 13. Global Gene Therapy Manufacturing Market Analysis, by Region
    • 13.1. Key Findings
    • 13.2. Gene Therapy Manufacturing Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
      • 13.2.1. North America
      • 13.2.2. Europe
      • 13.2.3. Asia Pacific
      • 13.2.4. Middle East
      • 13.2.5. Africa
      • 13.2.6. South America
  • 14. North America Gene Therapy Manufacturing Market Analysis
    • 14.1. Key Segment Analysis
    • 14.2. Regional Snapshot
    • 14.3. North America Gene Therapy Manufacturing Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 14.3.1. Product Type
      • 14.3.2. Therapy Type
      • 14.3.3. Workflow/Process
      • 14.3.4. Manufacturing Mode
      • 14.3.5. Scale of Operation
      • 14.3.6. Therapeutic Area
      • 14.3.7. End User
      • 14.3.8. Country
        • 14.3.8.1. USA
        • 14.3.8.2. Canada
        • 14.3.8.3. Mexico
    • 14.4. USA Gene Therapy Manufacturing Market
      • 14.4.1. Country Segmental Analysis
      • 14.4.2. Product Type
      • 14.4.3. Therapy Type
      • 14.4.4. Workflow/Process
      • 14.4.5. Manufacturing Mode
      • 14.4.6. Scale of Operation
      • 14.4.7. Therapeutic Area
      • 14.4.8. End User
    • 14.5. Canada Gene Therapy Manufacturing Market
      • 14.5.1. Country Segmental Analysis
      • 14.5.2. Product Type
      • 14.5.3. Therapy Type
      • 14.5.4. Workflow/Process
      • 14.5.5. Manufacturing Mode
      • 14.5.6. Scale of Operation
      • 14.5.7. Therapeutic Area
      • 14.5.8. End User
    • 14.6. Mexico Gene Therapy Manufacturing Market
      • 14.6.1. Country Segmental Analysis
      • 14.6.2. Product Type
      • 14.6.3. Therapy Type
      • 14.6.4. Workflow/Process
      • 14.6.5. Manufacturing Mode
      • 14.6.6. Scale of Operation
      • 14.6.7. Therapeutic Area
      • 14.6.8. End User
  • 15. Europe Gene Therapy Manufacturing Market Analysis
    • 15.1. Key Segment Analysis
    • 15.2. Regional Snapshot
    • 15.3. Europe Gene Therapy Manufacturing Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 15.3.1. Product Type
      • 15.3.2. Therapy Type
      • 15.3.3. Workflow/Process
      • 15.3.4. Manufacturing Mode
      • 15.3.5. Scale of Operation
      • 15.3.6. Therapeutic Area
      • 15.3.7. End User
      • 15.3.8. Country
        • 15.3.8.1. Germany
        • 15.3.8.2. United Kingdom
        • 15.3.8.3. France
        • 15.3.8.4. Italy
        • 15.3.8.5. Spain
        • 15.3.8.6. Netherlands
        • 15.3.8.7. Nordic Countries
        • 15.3.8.8. Poland
        • 15.3.8.9. Russia & CIS
        • 15.3.8.10. Rest of Europe
    • 15.4. Germany Gene Therapy Manufacturing Market
      • 15.4.1. Country Segmental Analysis
      • 15.4.2. Product Type
      • 15.4.3. Therapy Type
      • 15.4.4. Workflow/Process
      • 15.4.5. Manufacturing Mode
      • 15.4.6. Scale of Operation
      • 15.4.7. Therapeutic Area
      • 15.4.8. End User
    • 15.5. United Kingdom Gene Therapy Manufacturing Market
      • 15.5.1. Country Segmental Analysis
      • 15.5.2. Product Type
      • 15.5.3. Therapy Type
      • 15.5.4. Workflow/Process
      • 15.5.5. Manufacturing Mode
      • 15.5.6. Scale of Operation
      • 15.5.7. Therapeutic Area
      • 15.5.8. End User
    • 15.6. France Gene Therapy Manufacturing Market
      • 15.6.1. Country Segmental Analysis
      • 15.6.2. Product Type
      • 15.6.3. Therapy Type
      • 15.6.4. Workflow/Process
      • 15.6.5. Manufacturing Mode
      • 15.6.6. Scale of Operation
      • 15.6.7. Therapeutic Area
      • 15.6.8. End User
    • 15.7. Italy Gene Therapy Manufacturing Market
      • 15.7.1. Country Segmental Analysis
      • 15.7.2. Product Type
      • 15.7.3. Therapy Type
      • 15.7.4. Workflow/Process
      • 15.7.5. Manufacturing Mode
      • 15.7.6. Scale of Operation
      • 15.7.7. Therapeutic Area
      • 15.7.8. End User
    • 15.8. Spain Gene Therapy Manufacturing Market
      • 15.8.1. Country Segmental Analysis
      • 15.8.2. Product Type
      • 15.8.3. Therapy Type
      • 15.8.4. Workflow/Process
      • 15.8.5. Manufacturing Mode
      • 15.8.6. Scale of Operation
      • 15.8.7. Therapeutic Area
      • 15.8.8. End User
    • 15.9. Netherlands Gene Therapy Manufacturing Market
      • 15.9.1. Country Segmental Analysis
      • 15.9.2. Product Type
      • 15.9.3. Therapy Type
      • 15.9.4. Workflow/Process
      • 15.9.5. Manufacturing Mode
      • 15.9.6. Scale of Operation
      • 15.9.7. Therapeutic Area
      • 15.9.8. End User
    • 15.10. Nordic Countries Gene Therapy Manufacturing Market
      • 15.10.1. Country Segmental Analysis
      • 15.10.2. Product Type
      • 15.10.3. Therapy Type
      • 15.10.4. Workflow/Process
      • 15.10.5. Manufacturing Mode
      • 15.10.6. Scale of Operation
      • 15.10.7. Therapeutic Area
      • 15.10.8. End User
    • 15.11. Poland Gene Therapy Manufacturing Market
      • 15.11.1. Country Segmental Analysis
      • 15.11.2. Product Type
      • 15.11.3. Therapy Type
      • 15.11.4. Workflow/Process
      • 15.11.5. Manufacturing Mode
      • 15.11.6. Scale of Operation
      • 15.11.7. Therapeutic Area
      • 15.11.8. End User
    • 15.12. Russia & CIS Gene Therapy Manufacturing Market
      • 15.12.1. Country Segmental Analysis
      • 15.12.2. Product Type
      • 15.12.3. Therapy Type
      • 15.12.4. Workflow/Process
      • 15.12.5. Manufacturing Mode
      • 15.12.6. Scale of Operation
      • 15.12.7. Therapeutic Area
      • 15.12.8. End User
    • 15.13. Rest of Europe Gene Therapy Manufacturing Market
      • 15.13.1. Country Segmental Analysis
      • 15.13.2. Product Type
      • 15.13.3. Therapy Type
      • 15.13.4. Workflow/Process
      • 15.13.5. Manufacturing Mode
      • 15.13.6. Scale of Operation
      • 15.13.7. Therapeutic Area
      • 15.13.8. End User
  • 16. Asia Pacific Gene Therapy Manufacturing Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. Asia Pacific Gene Therapy Manufacturing Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Product Type
      • 16.3.2. Therapy Type
      • 16.3.3. Workflow/Process
      • 16.3.4. Manufacturing Mode
      • 16.3.5. Scale of Operation
      • 16.3.6. Therapeutic Area
      • 16.3.7. End User
      • 16.3.8. Country
        • 16.3.8.1. China
        • 16.3.8.2. India
        • 16.3.8.3. Japan
        • 16.3.8.4. South Korea
        • 16.3.8.5. Australia and New Zealand
        • 16.3.8.6. Indonesia
        • 16.3.8.7. Malaysia
        • 16.3.8.8. Thailand
        • 16.3.8.9. Vietnam
        • 16.3.8.10. Rest of Asia Pacific
    • 16.4. China Gene Therapy Manufacturing Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Product Type
      • 16.4.3. Therapy Type
      • 16.4.4. Workflow/Process
      • 16.4.5. Manufacturing Mode
      • 16.4.6. Scale of Operation
      • 16.4.7. Therapeutic Area
      • 16.4.8. End User
    • 16.5. India Gene Therapy Manufacturing Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Product Type
      • 16.5.3. Therapy Type
      • 16.5.4. Workflow/Process
      • 16.5.5. Manufacturing Mode
      • 16.5.6. Scale of Operation
      • 16.5.7. Therapeutic Area
      • 16.5.8. End User
    • 16.6. Japan Gene Therapy Manufacturing Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Product Type
      • 16.6.3. Therapy Type
      • 16.6.4. Workflow/Process
      • 16.6.5. Manufacturing Mode
      • 16.6.6. Scale of Operation
      • 16.6.7. Therapeutic Area
      • 16.6.8. End User
    • 16.7. South Korea Gene Therapy Manufacturing Market
      • 16.7.1. Country Segmental Analysis
      • 16.7.2. Product Type
      • 16.7.3. Therapy Type
      • 16.7.4. Workflow/Process
      • 16.7.5. Manufacturing Mode
      • 16.7.6. Scale of Operation
      • 16.7.7. Therapeutic Area
      • 16.7.8. End User
    • 16.8. Australia and New Zealand Gene Therapy Manufacturing Market
      • 16.8.1. Country Segmental Analysis
      • 16.8.2. Product Type
      • 16.8.3. Therapy Type
      • 16.8.4. Workflow/Process
      • 16.8.5. Manufacturing Mode
      • 16.8.6. Scale of Operation
      • 16.8.7. Therapeutic Area
      • 16.8.8. End User
    • 16.9. Indonesia Gene Therapy Manufacturing Market
      • 16.9.1. Country Segmental Analysis
      • 16.9.2. Product Type
      • 16.9.3. Therapy Type
      • 16.9.4. Workflow/Process
      • 16.9.5. Manufacturing Mode
      • 16.9.6. Scale of Operation
      • 16.9.7. Therapeutic Area
      • 16.9.8. End User
    • 16.10. Malaysia Gene Therapy Manufacturing Market
      • 16.10.1. Country Segmental Analysis
      • 16.10.2. Product Type
      • 16.10.3. Therapy Type
      • 16.10.4. Workflow/Process
      • 16.10.5. Manufacturing Mode
      • 16.10.6. Scale of Operation
      • 16.10.7. Therapeutic Area
      • 16.10.8. End User
    • 16.11. Thailand Gene Therapy Manufacturing Market
      • 16.11.1. Country Segmental Analysis
      • 16.11.2. Product Type
      • 16.11.3. Therapy Type
      • 16.11.4. Workflow/Process
      • 16.11.5. Manufacturing Mode
      • 16.11.6. Scale of Operation
      • 16.11.7. Therapeutic Area
      • 16.11.8. End User
    • 16.12. Vietnam Gene Therapy Manufacturing Market
      • 16.12.1. Country Segmental Analysis
      • 16.12.2. Product Type
      • 16.12.3. Therapy Type
      • 16.12.4. Workflow/Process
      • 16.12.5. Manufacturing Mode
      • 16.12.6. Scale of Operation
      • 16.12.7. Therapeutic Area
      • 16.12.8. End User
    • 16.13. Rest of Asia Pacific Gene Therapy Manufacturing Market
      • 16.13.1. Country Segmental Analysis
      • 16.13.2. Product Type
      • 16.13.3. Therapy Type
      • 16.13.4. Workflow/Process
      • 16.13.5. Manufacturing Mode
      • 16.13.6. Scale of Operation
      • 16.13.7. Therapeutic Area
      • 16.13.8. End User
  • 17. Middle East Gene Therapy Manufacturing Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Middle East Gene Therapy Manufacturing Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Product Type
      • 17.3.2. Therapy Type
      • 17.3.3. Workflow/Process
      • 17.3.4. Manufacturing Mode
      • 17.3.5. Scale of Operation
      • 17.3.6. Therapeutic Area
      • 17.3.7. End User
      • 17.3.8. Country
        • 17.3.8.1. Turkey
        • 17.3.8.2. UAE
        • 17.3.8.3. Saudi Arabia
        • 17.3.8.4. Israel
        • 17.3.8.5. Rest of Middle East
    • 17.4. Turkey Gene Therapy Manufacturing Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Product Type
      • 17.4.3. Therapy Type
      • 17.4.4. Workflow/Process
      • 17.4.5. Manufacturing Mode
      • 17.4.6. Scale of Operation
      • 17.4.7. Therapeutic Area
      • 17.4.8. End User
    • 17.5. UAE Gene Therapy Manufacturing Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Product Type
      • 17.5.3. Therapy Type
      • 17.5.4. Workflow/Process
      • 17.5.5. Manufacturing Mode
      • 17.5.6. Scale of Operation
      • 17.5.7. Therapeutic Area
      • 17.5.8. End User
    • 17.6. Saudi Arabia Gene Therapy Manufacturing Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Product Type
      • 17.6.3. Therapy Type
      • 17.6.4. Workflow/Process
      • 17.6.5. Manufacturing Mode
      • 17.6.6. Scale of Operation
      • 17.6.7. Therapeutic Area
      • 17.6.8. End User
    • 17.7. Israel Gene Therapy Manufacturing Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Product Type
      • 17.7.3. Therapy Type
      • 17.7.4. Workflow/Process
      • 17.7.5. Manufacturing Mode
      • 17.7.6. Scale of Operation
      • 17.7.7. Therapeutic Area
      • 17.7.8. End User
    • 17.8. Rest of Middle East Gene Therapy Manufacturing Market
      • 17.8.1. Country Segmental Analysis
      • 17.8.2. Product Type
      • 17.8.3. Therapy Type
      • 17.8.4. Workflow/Process
      • 17.8.5. Manufacturing Mode
      • 17.8.6. Scale of Operation
      • 17.8.7. Therapeutic Area
      • 17.8.8. End User
  • 18. Africa Gene Therapy Manufacturing Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. Africa Gene Therapy Manufacturing Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Product Type
      • 18.3.2. Therapy Type
      • 18.3.3. Workflow/Process
      • 18.3.4. Manufacturing Mode
      • 18.3.5. Scale of Operation
      • 18.3.6. Therapeutic Area
      • 18.3.7. End User
      • 18.3.8. Country
        • 18.3.8.1. South Africa
        • 18.3.8.2. Egypt
        • 18.3.8.3. Nigeria
        • 18.3.8.4. Algeria
        • 18.3.8.5. Rest of Africa
    • 18.4. South Africa Gene Therapy Manufacturing Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Product Type
      • 18.4.3. Therapy Type
      • 18.4.4. Workflow/Process
      • 18.4.5. Manufacturing Mode
      • 18.4.6. Scale of Operation
      • 18.4.7. Therapeutic Area
      • 18.4.8. End User
    • 18.5. Egypt Gene Therapy Manufacturing Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Product Type
      • 18.5.3. Therapy Type
      • 18.5.4. Workflow/Process
      • 18.5.5. Manufacturing Mode
      • 18.5.6. Scale of Operation
      • 18.5.7. Therapeutic Area
      • 18.5.8. End User
    • 18.6. Nigeria Gene Therapy Manufacturing Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Product Type
      • 18.6.3. Therapy Type
      • 18.6.4. Workflow/Process
      • 18.6.5. Manufacturing Mode
      • 18.6.6. Scale of Operation
      • 18.6.7. Therapeutic Area
      • 18.6.8. End User
    • 18.7. Algeria Gene Therapy Manufacturing Market
      • 18.7.1. Country Segmental Analysis
      • 18.7.2. Product Type
      • 18.7.3. Therapy Type
      • 18.7.4. Workflow/Process
      • 18.7.5. Manufacturing Mode
      • 18.7.6. Scale of Operation
      • 18.7.7. Therapeutic Area
      • 18.7.8. End User
    • 18.8. Rest of Africa Gene Therapy Manufacturing Market
      • 18.8.1. Country Segmental Analysis
      • 18.8.2. Product Type
      • 18.8.3. Therapy Type
      • 18.8.4. Workflow/Process
      • 18.8.5. Manufacturing Mode
      • 18.8.6. Scale of Operation
      • 18.8.7. Therapeutic Area
      • 18.8.8. End User
  • 19. South America Gene Therapy Manufacturing Market Analysis
    • 19.1. Key Segment Analysis
    • 19.2. Regional Snapshot
    • 19.3. South America Gene Therapy Manufacturing Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 19.3.1. Product Type
      • 19.3.2. Therapy Type
      • 19.3.3. Workflow/Process
      • 19.3.4. Manufacturing Mode
      • 19.3.5. Scale of Operation
      • 19.3.6. Therapeutic Area
      • 19.3.7. End User
      • 19.3.8. Country
        • 19.3.8.1. Brazil
        • 19.3.8.2. Argentina
        • 19.3.8.3. Rest of South America
    • 19.4. Brazil Gene Therapy Manufacturing Market
      • 19.4.1. Country Segmental Analysis
      • 19.4.2. Product Type
      • 19.4.3. Therapy Type
      • 19.4.4. Workflow/Process
      • 19.4.5. Manufacturing Mode
      • 19.4.6. Scale of Operation
      • 19.4.7. Therapeutic Area
      • 19.4.8. End User
    • 19.5. Argentina Gene Therapy Manufacturing Market
      • 19.5.1. Country Segmental Analysis
      • 19.5.2. Product Type
      • 19.5.3. Therapy Type
      • 19.5.4. Workflow/Process
      • 19.5.5. Manufacturing Mode
      • 19.5.6. Scale of Operation
      • 19.5.7. Therapeutic Area
      • 19.5.8. End User
    • 19.6. Rest of South America Gene Therapy Manufacturing Market
      • 19.6.1. Country Segmental Analysis
      • 19.6.2. Product Type
      • 19.6.3. Therapy Type
      • 19.6.4. Workflow/Process
      • 19.6.5. Manufacturing Mode
      • 19.6.6. Scale of Operation
      • 19.6.7. Therapeutic Area
      • 19.6.8. End User
  • 20. Key Players/ Company Profile
    • 20.1. Andelyn Biosciences
      • 20.1.1. Company Details/ Overview
      • 20.1.2. Company Financials
      • 20.1.3. Key Customers and Competitors
      • 20.1.4. Business/ Industry Portfolio
      • 20.1.5. Product Portfolio/ Specification Details
      • 20.1.6. Pricing Data
      • 20.1.7. Strategic Overview
      • 20.1.8. Recent Developments
    • 20.2. Catalent, Inc.
    • 20.3. Charles River Laboratories
    • 20.4. Forge Biologics
    • 20.5. FUJIFILM Diosynth Biotechnologies
    • 20.6. Genetix Biotherapeutics
    • 20.7. Kaneka Eurogentec
    • 20.8. Lonza Group AG
    • 20.9. Merck KGaA
    • 20.10. Novartis AG
    • 20.11. Oxford Biomedica
    • 20.12. Recipharm AB
    • 20.13. Samsung Biologics
    • 20.14. Sarepta Therapeutics, Inc.
    • 20.15. Thermo Fisher Scientific
    • 20.16. WuXi Advanced Therapies
    • 20.17. Others

 

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150
USD 5950
USD 7750
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation